November 17, 2016 - By Winifred Garcia · 0 Comments
The stock of Tobira Therapeutics Incorporated (NASDAQ:TBRA) registered an increase of 16.67% in short interest. TBRA’s total short interest was 548,100 shares in November as published by FINRA. Its up 16.67% from 469,800 shares, reported previously. With 122,200 shares average volume, it will take short sellers 5 days to cover their TBRA’s short positions. The short interest to Tobira Therapeutics Incorporated’s float is 10.5%. The stock last traded at $42.09 per share. It is down 414.55% since March 31, 2016 and is uptrending. It has outperformed by 409.92% the S&P500.
Tobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $462.02 million. The Firm is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus . It currently has negative earnings. The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Out of 4 analysts covering Tobira Therapeutics (NASDAQ:TBRA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Tobira Therapeutics has been the topic of 5 analyst reports since October 23, 2015 according to StockzIntelligence Inc. The stock of Tobira Therapeutics Inc (NASDAQ:TBRA) has “Hold” rating given on Wednesday, September 21 by Cantor Fitzgerald. Cowen & Co initiated the stock with “Outperform” rating in Friday, November 13 report. As per Friday, October 23, the company rating was initiated by Leerink Swann. The firm has “Buy” rating given on Monday, April 11 by H.C. Wainwright. The stock has “Buy” rating given by Cantor Fitzgerald on Wednesday, July 6.
Tobira Therapeutics, Inc., formerly Regado Biosciences, Inc., incorporated on September 11, 2006, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat non-alcoholic steatohepatitis (NASH). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator that can be used to treat a number of disease states, such as NASH, fibrosis, inflammation and human immunodeficiency virus (HIV). CVC is a once-daily pill. CVC is a dual inhibitor of the Chemokine (C-C motif) receptor 2 (CCR2) and Chemokine (C-C motif) receptor 5 (CCR5) pathways, which play a role in the cycle of inflammation and fibrosis. CVC binds to both CCR2 and CCR5 targets. The Firm is evaluating CVC’s anti-fibrotic effects in liver disease models and antiviral effects on HIV-1.
More recent Tobira Therapeutics Inc (NASDAQ:TBRA) news were published by: Fool.com which released: “Why Tobira Therapeutics Inc Was an Overnight Octuple” on September 20, 2016. Also Prnewswire.com published the news titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on August 10, 2016. Marketwatch.com‘s news article titled: “Tobira Therapeutics’ stock loses half its value after trial misses primary …” with publication date: July 25, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia